Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
36.07
+0.81 (2.30%)
At close: Aug 13, 2025, 4:00 PM
35.50
-0.57 (-1.58%)
After-hours: Aug 13, 2025, 7:55 PM EDT
Revolution Medicines Stock Forecast
Stock Price Forecast
According to 12 professional analysts, the 12-month price target for Revolution Medicines stock ranges from a low of $56 to a high of $82. The average analyst price target of $69.42 forecasts a 92.46% increase in the stock price over the next year.
Price Target: $69.42 (+92.46%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 7 | 7 | 7 | 8 | 7 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 12 | 12 | 12 | 13 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $57 → $56 | Strong Buy | Maintains | $57 → $56 | +55.25% | Aug 7, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $65 | Strong Buy | Initiates | $65 | +80.21% | Jul 15, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +121.79% | Jun 25, 2025 |
| Needham | Needham | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +58.03% | Jun 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $73 → $72 | Strong Buy | Maintains | $73 → $72 | +99.61% | May 14, 2025 |
Financial Forecast
Revenue This Year
8.61M
Revenue Next Year
28.79M
from 8.61M
Increased by 234.26%
EPS This Year
-4.66
from -3.58
EPS Next Year
-5.06
from -4.66
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 65.6M | 151.2M | 636.5M |
| Avg | 8.6M | 28.8M | 159.5M |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 1,655.5% | 2,110.9% |
| Avg | - | 234.3% | 454.0% |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -3.58 | -4.26 | -0.77 |
| Avg | -4.66 | -5.06 | -4.82 |
| Low | -4.69 | -5.48 | -6.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.